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doi:10.1016/j.jfma.2011.08.009This study reported our experience of the clinical characteristics of periparotid recurrence of
nasopharyngeal carcinoma (NPC) after parotid-gland-sparing radiotherapy. We retrospectively
reviewed the charts of 296 patients with NPC who underwent parotid-gland-sparing radio-
therapy at the Tri-Service General Hospital from 1998 to 2008. Eighty-three patients underwent
three-dimensional conformal radiotherapy, and 205 patients underwent intensity-modulated
radiotherapy; parotid glands were spared bilaterally in all patients. None of these patients
had undergone previous radiotherapy or surgical treatment of the head and neck. Disease
recurred in a spared parotid gland in three patients (1.04%). Two of these patients had under-
gone three-dimensional conformal radiotherapy and the third underwent intensity-modulated
radiotherapy. All three patients had undergone parotidectomy. Adjuvant radiotherapy or
concurrent chemoradiation was administered. One patient died ofmetastatic disease 26months
after diagnosis of recurrence; the others were well with no evidence of disease at 63 and
6 months after initial recurrence. Periparotid recurrence is an uncommon pattern of locoregio-
nal failure after parotid-gland-sparing radiotherapy for NPC. Early diagnosis and aggressive
therapy for patients with periparotid recurrence may improve outcomes.
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656 D.-S. Lin et al.In nearly all patients with nasopharyngeal carcinoma (NPC)
who are treated with conventional radiotherapy, salivary
gland damage with subsequent xerostomia has been
unavoidable.1,2 To reduce or prevent xerostomia in patients
with NPC for whom radiotherapy is mandatory, investiga-
tors have used various approaches, including parotid-
gland-sparing three-dimensional conformal radiotherapy
(3DCRT)3,4 and intensity-modulated radiotherapy (IMRT), to
decrease the dose of radiation delivered to the parotids
and increase the dose delivered to the gross disease in the
nasopharynx.5e10
One concern with parotid-gland-sparing radiotherapy is
that reducing exposure of the salivary tissue to radiation
could result in inadequate radiation exposure to micro-
scopic disease in the region of a spared parotid gland. In
2008, Donald et al first reported on two patients with NPC
and one with squamous cell carcinoma of the tonsil who had
periparotid failure after definitive parotid-gland-sparing
IMRT.10 These three cases were the only published cases
of periparotid treatment failure in patients with head
and neck cancer who underwent definitive parotid-gland-
sparing radiotherapy.
In our institute, three patients who were treated with
parotid-gland-sparing radiotherapy later developed peri-
parotid recurrence of NPC. We report our experience with
these patients and discuss the clinical implications of per-
iparotid recurrence of NPC.
Patients and methods
Patients
We performed a retrospective chart review of 387 patients
with NPC who underwent radiotherapy at the Tri-Service
General Hospital, Taipei, Taiwan from 1998 to 2008. Among
them, 296 patients underwent parotid-gland-sparing radio-
therapy, and only 288 patients who completed the full
radiotherapy course were included. Eighty-three patients
underwent parotid-gland-sparing 3DCRT and 205 underwent
parotid-gland-sparing IMRT. The parotid glands were spared
as much as possible with the prerequisite that dose to the
target was not compromised. The parotid glands were
spared bilaterally in all cases. None of these patients had
undergone previous radiotherapy or surgery of the head
and neck.
Radiotherapy technique
The 3DCRT technique has been described previously [4].
The clinical target volume (CTV) included the gross target
volume (GTV) and the following: the medial pterygoid
muscles, the parapharyngeal spaces, the carotid space, the
sphenoid sinus, the posterior third to quarter of the nasal
cavity, and the anterior quarter to third of the clivus and
vertebral body. The lower margin was set at C2 in the
absence of oropharyngeal extension. We added 2 mm to all
the GTVs to become CTVs, and added 4 mm to all CTVs to
become planning target volumes (PTVs). In patients with
cavernous sinus or intracranial invasion, the cavernous
sinus and the entire sellar and suprasellar regions were
included. We added a 4-mm margin to the CTV to allow forsetup errors, except at the brainstem and the spinal cord,
where the margin was usually 2e4 mm for safety reasons.
Thus, the PTV equaled the CTV plus a 4-mm margin. The
lower neck and bilateral supraclavicular fossae were irra-
diated in all patients with 5000 cGy. A single PTV was used
throughout the treatment course without reduction.
For IMRT, the simultaneous integrated boost technique
was used. CTV1 encompassed the gross tumor with a 0.4-cm
margin, CTV2 covered the high-risk areas such as level IIeIII
of the neck, and CTV3 included bilateral level IV and supra-
and infra-clavicular areas. A dose of 6800e7400 cGy was
given for PTV1, which encompassed the gross tumor with
a margin of 0.4 cm, 6000 cGy to PTV2, and 5000e5400 cGy
to PTV3.Results
Three patients (1.04%) had disease recurrence in a spared
parotid gland. Two of them (patients 1 and 2) had under-
gone parotid-gland-sparing 3DCRT and the third had
undergone parotid-gland-sparing IMRT. Two patients (1 and
3) had unilateral nodal disease ipsilateral to the primary
tumor. Patient 2 had bilateral lymphadenopathy. Summa-
ries of the patient characteristics before and after peri-
parotid recurrence are provided in Tables 1 and 2.
Case 1
Pre-therapy computed tomography showed no parotid lesion
(Fig. 1A). Twenty-one months after having no evidence
of disease, the patient noted a swelling over her left pre-
auricular region. Computed tomography demonstrated an
enhancing enlarged node in the left periparotid and intra-
parotid region, suggesting tumor recurrence (Fig. 1B). Fine
needle aspiration confirmed the presence of a metastatic
undifferentiated carcinoma.
Left parotidectomy and neck dissection were performed,
and pathological examination showed metastatic undiffer-
entiated carcinoma in the intraparotid and periparotid
lymph nodes, with extranodal extension. The margin status
showed no malignancy, no extracapsular extension, and no
lymphovascular or perineural invasion. The patient under-
went adjuvant chemotherapy, and she declined adjuvant
radiotherapy. The patient died with bony and intracranial
metastases 26 months after recurrence.
Case 2
Pre-therapy magnetic resonance imaging (MRI) showed no
parotid lesion (Fig. 2A). Six months after having no
evidence of disease, the patient noted a swelling in his right
pre-auricular region. A superficial nonspecific 7-mm parotid
nodule had been noted within the superficial aspect of the
right parotid on pretreatment MRI (Fig. 2B).
Right parotidectomy and neck dissectionwere performed,
and pathological examination showed an intraparotid lymph
node of metastatic undifferentiated carcinoma. The margin
status showed no malignancy, no extracapsular extension,
and no lymphovascular or perineural invasion. The patient
declined chemotherapy and underwent IMRT (50 Gy) of the
Table 1 Patient characteristics at initial diagnosis
Characteristic Patient 1 Patient 2 Patient 3
Sex Female Male Male
Age (yr) 51 49 46
Lymph nodes L neck level II R neck level IIeIII L neck level IIeIII
L neck level II
R retropharynx
Stage T4bN1M0 T2bN2M0 T4N2M0
RT technique 3DCRT 3DCRT IMRT
RT dose:
PTV1 8180 cGy 7000 cGy 7500 cGy
PTV2 6480 cGy 7000 cGy 6000 cGy
PTV3 5400 cGy 5040 cGy 5040 cGy
Chemotherapy
Concurrent Cisplatin  3 Cisplatin  3 Cisplatin  3
Adjuvant Cisplatin plus 5-FU  3 Cisplatin plus 5-FU  3
Mean parotid dose/estimated
dose at the recurrent site
2705 cGy/1500 cGy 6200 cGy/4000 cGy 4450 cGy/7000 cGy
LZ left; RZ right; RTZ radiotherapy; 3DCRTZ three-dimensional conformal radiotherapy; IMRTZ intensity modulated radiotherapy;
PTV Z planning target volume; 5-FU Z 5-fluorouracil.
Parotid recurrence of nasopharyngeal carcinoma 657recurrence site. At last follow-up, the patient was well with
no evidence of disease 63 months after recurrence.
Case 3
Pre-therapy MRI showed no parotid lesion (Fig. 3A and 3B).
The patient noted a swelling over his left pre-auricular
region 52 months after initial treatment. There was an
enlarged mass in the left parotid gland, measuring about
3.3 cm in the long axis, with perifocal edematous changes
of the gland (Fig. 3C). Whole-body bone scan and abdom-
inal sonography revealed no metastasis at other sites. Fine
needle aspiration confirmed the presence of a metastatic
undifferentiated carcinoma.
Left parotidectomy was performed, and pathological
examination showed an intraparotid lymph node of meta-
static undifferentiated differentiated carcinoma.Themargin
status showed no malignancy, no extracapsular extension,
and no lymphovascular or perineural invasion. The patientTable 2 Patient characteristics after recurrence
Characteristic Patient 1 Pat
Time to recurrence (mo) 21 6
Recurrence site L periparotid and intraparotid
lymph nodes
R in
Imaging findings at disease
recurrence
Enhanced 6-mm and 4-mm
nodules within left parotid
gland
Enh
righ
Surgery after recurrence L parotidectomy þ ND, level II R p
Treatment after surgery Chemotherapy Adj
Outcome (months after
recurrence)
Died (26) No
L Z left; R Z right; ND Z neck dissection; IMRT Z intensity modulareceived 45 Gy of IMRT to the recurrence with concurrent
chemotherapy and adjuvant chemotherapy. At last follow-
up, 6 months after recurrence, the patient was well with no
evidence of disease.
Discussion
The recurrence of head and neck cancer in spared parotid
gland was first reported by Chao et al11 in a patient with
hypopharyngeal cancer who had undergone IMRT post-
operatively, following partial pharyngectomy and neck
dissection. It is possible that, in postoperative patients,
altered lymphatic anatomy could contribute to different
patterns of locoregional recurrence, and that parotid gland
sparing may play only a small role. In 2008, Donald et al
reported that two patients with NPC and one with squamous
cell carcinoma of the tonsil developed periparotid failure
after definitive parotid-gland-sparing IMRT. These three
cases were the only published cases of periparotid failure inient 2 Patient 3
52
traparotid lymph nodes L intraparotid lymph nodes
anced 7-mm nodule within
t parotid gland
Enhanced 3.3-cm nodule with
perifocal edematous change
within left parotid gland
arotidectomy þ ND, level II L parotidectomy
uvant IMRT with 5000 cGy Adjuvant IMRT with 4500 cGy
and concurrent chemotherapy
evidence of disease (63) No evidence of disease (6)
ted radiotherapy.
Figure 1 (A) Pre-therapy computed tomography showed no
parotid lesion. (B) Computed tomography showed enhanced
6-mm (arrow) and 4-mm nodules within the left parotid gland. Figure 2 (A) Pre-therapy magnetic resonance imaging
showed no parotid lesion. (B): Magnetic resonance imaging
showed an enhanced 7-mm nodule within the right parotid
gland (arrow).
658 D.-S. Lin et al.patients who underwent definitive parotid-gland-sparing
IMRT. The authors suggested that the presence of multi-
level nodal disease and periparotid nodules on pretreat-
ment imaging should raise suspicion of subclinical disease
inside the seemingly harmless nodules, although they do not
meet radiographic or clinical criteria for possible gross
disease [10]. In our three patients, the cause of recurrence
remains elusive. Many factors may contribute to thedevelopment of recurrence, including later stage of disease,
pre-existing metastasis at the periparotid area, and over-
protection of the parotid gland during radiotherapy.
Metastasis of NPC may also occur at the parotid nodes.
The parotid gland may also be involved by extracapsular
Figure 3 (A) Pre-therapy magnetic resonance imaging showed no parotid lesion. (B) Treatment-planning with iso-dose curve.
(C) Magnetic resonance imaging showed an enhanced 3.3-cm nodule with perifocal edematous change within the left parotid gland
(arrow).
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by the primary lesion in the nasopharynx.12 It would seem
not powerful enough to draw any conclusions about the
exact causes of the recurrence. Among the 288 patients
treated with parotid-gland-sparing radiotherapy, peripar-
otid recurrence occurred in only three patients (1.04%).
Although there may be more periparotid recurrences during
extended follow-up, a significant increase in incidence
seems unlikely. In our experience, patients treated with
parotid-gland-sparing 3DCRT or IMRT have better overall
survival and less xerostomia as compared to patients
treated with conventional radiotherapy.4 The 3-year local
control rate and progression-free survival rate of our NPC
patients treated with 3DCRT were 86e96% and 80.3%,
respectively.4 Therefore, parotid-gland-sparing 3DCRT or
IMRT appear to be worth adopting.
The best treatment for periparotid failure after parotid-
gland-sparing radiotherapy for NPC has not been deter-
mined. We chose parotidectomy followed by adjuvant
radiotherapy or chemotherapy, or both, as our salvage
procedure. Patient 1 in our series died 26 months after
recurrence due to bony and intracranial metastasis; the
others remained well with no evidence of disease at 63 and6 months after recurrence, suggesting that aggressive
therapy can help to optimize the prognosis for periparotid
recurrence. However, regular physical examinations and
imaging studies of the parotid gland are required for
patients who are treated with parotid-gland-sparing radio-
therapy for NPC.
In conclusion, our study shows that periparotid recur-
rence is an uncommon type of locoregional failure after
parotid-gland-sparing radiotherapy for patients with NPC.
Although the etiology of periparotid recurrence is unclear,
early diagnosis and aggressive treatment of periparotid
recurrence may help to optimize outcomes.
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